Screening for prostate cancer in military populations

Military Medicine

Volumn 170, Issue 11, 2005, Pages 905-914

  Moul, Judd W ^a,b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; HIGH RISK PATIENT; HUMAN; MALE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SOLDIER; SURVIVAL RATE;

EID: 27744600911     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.170.11.905     Document Type: Review

References (103)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M: Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Walsh PC: Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med 1993; 119: 948-9.
3. Woolf SH: Screening prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med 1995; 333: 1401-5.
4. Mettlin C, Jones G, Avetett H, et al: Defining and updating the American Cancer Society guidelines for the cancer-related check-up: prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 42-6.
5. American Urological Association: Early detection of prostate cancer: use of transrectal ultrasound. In: American Urological Association 1992 Policy Statement Book, pp 4-20. Baltimore, MD, American Urological Association, 1992.
6. U.S. Preventive Services Task Force: Screening for prostate cancer. In: Guide to Clinical Preventive Services, Ed 2, p 119. Baltimore, MD, Williams & Wilkins, 1996.
7. American College of Physicians: Screening for prostate cancer. Ann Intern Med 1997; 126: 480-4.
8. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54.
9. Catalona WJ: Screening for prostate cancer [letter]. N Engl J Med 1996; 334: 666-7.
10. Morrison AS: The effects of early treatment, lead time, and length time bias on the mortality experienced by cases detected by screening. Int J Epidemiol 1982; 11: 261.
11. Jacobson SJ, Katusic SK, Bergstralh EJ, et al: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen. JAMA 1995; 274: 1445-9.
12. Stephenson RA: Population-based prostate cancer trends in the PSA era: data from the Surveillance. Epidemiology, and End Results (SEER) Program. Monogr Urol 1998; 19: 3-19.
13. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444-8.
14. Schwartz KL, Serverson RK, Gurney JG, Montie JE: Trends in the stage-specific incidence of prostate carcinoma in the Detroit metropolitan area. Cancer 1996; 78: 1260.
15. Threlfall TJ, English DR. Rouse IL: Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust 1998; 169: 21.
16. Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobson SJ: Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, MN. J Urol 1999; 161: 529.
17. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604.
18. Lefevre ML: Prostate cancer screening: more harm than good? Am Fam Physician 1998; 58: 432.
19. Sun L, Gancarczyk K, Paquette EL, et al: Introduction to Department of Defense Center for Prostate Disease Research multicenter national prostate cancer database and analysis in the PSA era. Urol Oncol 2001; 6: 203-9.
20. Oesterling JE, Jacobson SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860.
21. Morgan TO, Jacobson SJ, McCarthy WF, et al: Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304.
22. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK: Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease. 1974 to 1994. J Urol 1997; 158: 1427.
23. Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee WR: Localized carcinoma of the prostate (stages T1b, T1b, T2, and T3): review of management with external beam radiation therapy. Cancer 1993; 72: 3156.
24. Catalona WJ, Smith DS: 5-year recurrence rates after anatomic radical retropubic prostectectomy for prostate cancer. J Urol 1994; 153: 1837.
25. Smith DS, Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 1732.
26. Gilliland FD, Hunt WC, Key CR: Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era. Urology 1996; 48: 67.
27. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF: Cancer surveillance series: interpreting trends in prostate cancer, part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1033.
28. Paquette EL, Connelly RR, Sesterhenn IA, et al: Improvements in pathologic staging for African American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. Cancer 2001; 92: 2673-9.
29. Labrie F, Candas B, Dupont A, et al: Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83.
30. Bartsch G, Hominger W, Klocker H, et al: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol. Austria. Urology 2001; 58: 417-24.
31. Barry MJ, Roberts RG: Indications for PSA testing. JAMA 1997; 277: 955.
32. Smith RA, Von Eschenbach AC, Wender R, et al: American Cancer Society guidelines for early detection of cancer: update of early detection guidelines for prostate, colorectal and endometrial cancers. CA Cancer J Clin 2001; 51: 38-75.
33. American Urological Association: Prostate-specific antigen (PSA) best practice policy. Oncology 2000; 14: 267-86.
34. Moul JW: Screening for prostate cancer in African Americans. Curr Urol Rep 2000; 1: 57-64.
35. Young CD, Lewis P, Weinberg V, et al: The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy. Semin Urol Oncol 2000; 18: 121-6.
36. Fowler JE Jr, Bigler SA: Racial differences in prostate carcinogenesis: histologic and clinical observations. Urol Clin North Am 2002; 29: 183-91.
37. Fowler JE Jr, Bigler SA, Farabaugh PB, Wilson SS: Prostate cancer detection in black and white men with abnormal digital rectal examination and prostate specific antigen less then 4 ng/mL. J Urol 2000; 164: 1961-3.
38. Bunker CH, Patrick AL, Konety BR, et al: High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev 2002; 11: 726-9.
39. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC: Family history and the risk of prostate cancer. Prostate 1990; 17: 337-47.
40. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR: Familial patterns of prostate cancer: a case-control analysis. J Urol 1991; 146: 1305-7.
41. Gronberg H, Damber L, Damber JE: Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152: 1484-7.
42. Gronberg H, Damber L, Damber JE: Familial prostate cancer in Sweden. Cancer 1996; 77: 138-43.
43. Bauer JJ, Srivastava S, Connelly RR, et al: Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998; 51: 970-6.
44. Valeri A, Cormier L, Moineau MP, et al: Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first-degree relatives. J Urol 2002; 168: 483-7.
45. Gann PH, Hennekens CH, Stamfer JJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995; 273: 289-94.
46. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB: Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58: 411-6.
47. DeAntoni EP, Crawford ED, Oesterling JE, et al: Age- and race-specific reference ranges for prostate-specific antigen from a large community base study. Urology 1996; 48: 234-8.
48. Hartzell JD, Kao T, Holland JC, et al: Age-specific reference ranges for prostate specific antigen in young men: retrospective study from the National Defense University. Prostate J 2002; 3: 36-41.
49. Chautard D, Daver A, Mermod B, Tichet A, Bocquillon V, Soret JY: Values for the free to total prostate-specific antigen ratio as a function of age: necessity of reference range validation. Eur Urol 1999; 36: 181-6.
50. Weinrich MC, Jacobsen SJ, Weinrich SP, et al: Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology 1998; 52: 967-73.
51. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090-5.
52. Anderson JR, Strickland D, Corbin D, Byrnes JA, Zweiback E: Age-specific reference ranges for serum prostate-specific antigen. Urology 1995; 46: 54-7.
53. Cooney KA, Strawderman MS, Wojno KJ, et al: Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 2001; 57: 91-6.
54. Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J: Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 1995; 154: 1090-5.
55. Preston DM, Levin LI, Jacobson DJ, et al: Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 2000; 56: 812-6.
56. Moul JW, Connely RR, Barko WF, Vaitkus M: Should healthy men between the age of 40-49 be screened for prostate cancer? A Department of Defense (DOD), Center for Prostate Disease Research (CPDR), and Army Physical Fitness Research Institute (APFRI) prospective study at the U.S. Army War College (US-AWC). J Urol 1999; 163(Suppl): 4.
57. Moul JW, Sesterhenn IA, Connelly RR, et al: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995; 274: 1277-81.
58. Smith DS, Carvalhal GF, Mager DE, Bullock AD, Cantolona WJ: Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998; 160: 1734-8.
59. Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R: Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/mL combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 2001; 166: 851-5.
60. Nixon RG, Lilly JD, Liedtke RJ, Batjer JD: Variation of free and total prostate-specific antigen levels: the effect on the percent free/total prostate-specific antigen. Arch Pathol Lab Med 1997; 121: 385-91.
61. Prestigiacomo AF, Stamey TA: Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/mL range in male volunteers. J Urol 1996; 155: 1977-80.
62. Morote J, Encabo G, Lopez M, De Torres IM: Individual variations of total and percent free serum prostatic specific antigen: could they change the indication of prostatic biopsy? Oncol Rep 1999; 6: 887-90.
63. Orastein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WJ: Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157: 2179-82.
64. Eastham JA, Riedel E, Scardino PT, et al: Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289: 2695-700.
65. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE: Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47: 511-6.
66. Netto NR Jr, Apuzzo F, de Andrade E, Srulzon GB, Cortado PL, Lima ML: The effects of ejaculation on serum prostate specific antigen. J Urol 1996; 155: 1329-31.
67. Heidenreich A, Vorreuther R, Neubauer S, Westphal J, Engelmann UH, Moul JW: The influence of ejaculation on serum levels of prostate specific antigen. J Urol 1997; 157: 209-11.
68. Herschman JD, Smith DS, Catalona WJ: Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 1997; 50: 239-43.
69. Yavascaoglu I, Savci V, Oktay B, Simsek U, Ozyurt M: The effects of ejaculation on serum prostate-specific antigen (PSA). Int Urol Nephrol 1998; 30: 53-8.
70. Stenner J, Holthaus K, Mackenzie SH, Crawford ED: The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology 1998; 51: 455-9.
71. Zisman A, Soffer Y, Siegel YI, Paz A, Lindner A: Postejaculation serum prostate-specific antigen level. Eur Urol 1997; 32: 54-7.
72. Kao GD, Devine P: Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 2000; 88: 615-9.
73. Jones HA, Metz JM, Devine P, Hahn SM, Whittington R: Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions. Urology 2002; 59: 272-6.
74. Ostrow MJ, Cornelisse PG, Heath KV, et al: Determinants of complementary therapy use in human immunodeficiency virus-infected individuals receiving antiretroviral or anti-opportunistic agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 115-20.
75. Allen T, Thomson WM, Emmerton LM, Poulton R: Nutritional supplement use among 26-year-olds. N Z Med J 2000; 113: 274-7.
76. Heuschkel R, Afzal N, Wuerth A, et al: Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002; 92: 382-8.
77. Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998; 51: 1003-7.
78. Carraro JC, Raynaud JP, Koch G, et al: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1.098 patients. Prostate 1996; 29: 231-40.
79. Guess HA, Gormley GJ, Stoner E, Oesterling JE: The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155: 3-9.
80. Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD: Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998; 159: 441-3.
81. Douglas TH, Connelly RR. McLeod DG, Erickson SJ, Barren R III, Murphy GP: Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995; 59: 246-50.
82. Oremek GM, Seiffert UB: Physical activity releases prostate specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. Clin Chem 1996; 42: 691-5.
83. Crawford ED III, Mackenzie SH, Safford HR, Capriola M: The effect of bicycle riding on serum prostate specific antigen levels. J Urol 1996; 156: 103-5.
84. Swain RA, Montalto N, Ross D: The effect of long-distance cycling on the prostate-specific antigen level. Arch Fam Med 1997; 6: 500-2.
85. Leventhal EK, Rozanski TA, Morey AF, Rholl V: The effects of exercise and activity on serum prostate specific antigen levels. J Urol 1993; 150: 893-4.
86. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ: Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 1998; 31: 127-31.
87. Roehl KA, Antenor JA, Catalona WJ: Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/mL range. J Urol 2002; 168: 922-5.
88. Haese A, Dworschack RT, Partin AW: Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng/mL range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng/mL range, J Urol 2002; 168: 504-8.
89. Fang J, Metter EJ, Landis P, Carter HB: PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL. Urology 2002; 59: 889-93.
90. Ellis WJ, Etzioni R, Vessella RL, Hu C, Goodman GE: Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. J Urol 2001; 166: 93-8.
91. Crawford ED, Chia D, Andriole GL, et al: PSA testing interval reduction in screening intervals: data from the Prostate, Lung, Colorectal and Ovarian cancer (PLCO) screening trial. Proc ASCO 2002; 21.
92. Brawer MK, Meyer GE, Letran JL, et al: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8.
93. Brawer MK, Cheli CD, Neaman IE, et al: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80.
94. Maeda H, Arai Y, Aoki Y, Okubo K, Okada T, Maekawa S: Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology 1999; 54: 225-8.
95. Okihara K, Cheli CD, Partin AW, et al: Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167: 2017-23.
96. Tanguay S, Begin LR, Elhilali MM, et al: Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59: 261-5.
97. Okihara K, Pritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ: Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/mL. J Urol 2001; 165: 1930-6.
98. Horninger W, Cheli CD, Babaian RJ, et al: Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002; 60(Suppl 1): 31-5.
99. Lein M, Kwiatkowski M, Semjonow A, et al: A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003; 170: 1175-9.
100. Petricoin EF III, Ardekani AM, Liotta LA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
101. Adam BL, Qu Y, Wright GL Jr, et al: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-14.
102. Cazares LH, Adam BL, Wright GL Jr, et al: Normal, benign, preneoplastic and malignant cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002; 8: 2541-52.
103. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM: Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335-42.